More articles 2014-10-03 12:14:30The latest scientific breakthroughs on skin and its functions may have arrived with a small change to a widely used skin-care product.
A study in the journal Nature Communications says that when applied topically, the new formulation of the skin-whitening drug Biodermapinib (BOD) may improve the effectiveness of previous formulations of the drug, but may also lower its effectiveness over time.
The drug, which was developed by AstraZeneca and is already on the market, was initially approved in 2008 by the European Union to treat skin cancer but has since been withdrawn due to side effects.
While there is a lot of uncertainty about the effectiveness and safety of BOD, scientists say that its ingredients have been studied extensively to make sure that it has been effective in the past.
According to the study, BOD’s new formulation was more effective than a previous formulation that was applied topical.
In the study published in the Journal of Investigative Dermatology, the researchers examined BOD from different concentrations of the formulation in skin, and found that it did not significantly alter the overall appearance of the patient’s skin.
The researchers concluded that while there are significant side effects, the formulation’s efficacy is not likely to change with use.
In other words, Bod’s new formula appears to be a safe and effective treatment option for patients with non-melanoma skin.
But it may not be the best choice for people with melanoma.
The National Cancer Institute says that it recommends that people with nonmelanomas go for the most effective treatment that has been proven effective.
The institute is not recommending that people apply the BOD product as a whole, as some experts have suggested.
However, the institute recommends that doctors and patients consider the best way to apply the drug.
If you or anyone you know needs treatment, contact your doctor.